Cargando…
Endogenous Bak inhibitors Mcl-1 and Bcl-x(L): differential impact on TRAIL resistance in Bax-deficient carcinoma
Tumor necrosis factor (α)–related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent that preferentially kills tumor cells with limited cytotoxicity to nonmalignant cells. However, signaling from death receptors requires amplification via the mitochondrial apoptosis pathway (type II)...
Autores principales: | Gillissen, Bernhard, Wendt, Jana, Richter, Antje, Richter, Anja, Müer, Annika, Overkamp, Tim, Gebhardt, Nina, Preissner, Robert, Belka, Claus, Dörken, Bernd, Daniel, Peter T. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2845080/ https://www.ncbi.nlm.nih.gov/pubmed/20308427 http://dx.doi.org/10.1083/jcb.200912070 |
Ejemplares similares
-
Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent ‘type I' mode
por: Gillissen, B, et al.
Publicado: (2013) -
Mcl-1 determines the Bax dependency of Nbk/Bik-induced apoptosis
por: Gillissen, Bernhard, et al.
Publicado: (2007) -
Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes
por: Seiller, Carolane, et al.
Publicado: (2020) -
MCL-1ES Induces MCL-1L-Dependent BAX- and BAK-Independent Mitochondrial Apoptosis
por: Kim, Jae-Hong, et al.
Publicado: (2013) -
Pan-class I PI3-kinase inhibitor BKM120 induces MEK1/2-dependent mitotic catastrophe in non-Hodgkin lymphoma leading to apoptosis or polyploidy determined by Bax/Bak and p53
por: Müller, Anja, et al.
Publicado: (2018)